1160756-77-3 Usage
Uses
Used in Pharmaceutical Research and Development:
(1R)-1-cyclobutyl-2,2,2-trifluoroethanamine hydrochloride is used as a building block in organic synthesis for the development of pharmaceuticals. Its unique structure and potential antineoplastic activity make it a promising candidate for the treatment of various diseases and disorders.
Used in Organic Synthesis:
(1R)-1-cyclobutyl-2,2,2-trifluoroethanamine hydrochloride is used as a key intermediate in the synthesis of complex organic molecules, particularly in the development of new pharmaceutical agents.
Used in Antineoplastic Applications:
(1R)-1-cyclobutyl-2,2,2-trifluoroethanamine hydrochloride is used as a potential antineoplastic agent for the treatment of cancer. Its cyclobutyl and trifluoromethyl groups may contribute to its ability to target and inhibit the growth of cancer cells.
Used in Neurological Applications:
(1R)-1-cyclobutyl-2,2,2-trifluoroethanamine hydrochloride may have potential applications in the treatment of neurological conditions due to its unique structure and potential biological activity. Further research is needed to explore its therapeutic potential in this area.
Check Digit Verification of cas no
The CAS Registry Mumber 1160756-77-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,6,0,7,5 and 6 respectively; the second part has 2 digits, 7 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1160756-77:
(9*1)+(8*1)+(7*6)+(6*0)+(5*7)+(4*5)+(3*6)+(2*7)+(1*7)=153
153 % 10 = 3
So 1160756-77-3 is a valid CAS Registry Number.
1160756-77-3Relevant academic research and scientific papers
Discovery of 1-amino-5 H-pyrido[4,3-b]indol-4-carboxamide inhibitors of janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders
Lim, Jongwon,Taoka, Brandon,Otte, Ryan D.,Spencer, Kerrie,Dinsmore, Christopher J.,Altman, Michael D.,Chan, Grace,Rosenstein, Craig,Sharma, Sujata,Su, Hua-Poo,Szewczak, Alexander A.,Xu, Lin,Yin, Hong,Zugay-Murphy, Joan,Marshall, C. Gary,Young, Jonathan R.
, p. 7334 - 7349 (2011/12/04)
The JAK-STAT pathway mediates signaling by cytokines, which control survival, proliferation, and differentiation of a variety of cells. In recent years, a single point mutation (V617F) in the tyrosine kinase JAK2 was found to be present with a high incidence in myeloproliferative disorders (MPDs). This mutation led to hyperactivation of JAK2, cytokine-independent signaling, and subsequent activation of downstream signaling networks. The genetic, biological, and physiological evidence suggests that JAK2 inhibitors could be effective in treating MPDs. De novo design efforts of new scaffolds identified 1-amino-5H-pyrido[4,3-b]indol-4-carboxamides as a new viable lead series. Subsequent optimization of cell potency, metabolic stability, and off-target activities of the leads led to the discovery of 7-(2-aminopyrimidin-5-yl)-1- {[(1R)-1-cyclopropyl-2,2,2-trifluoroethyl]amino}-5H-pyrido[4,3-b] indole-4-carboxamide (65). Compound 65 is a potent, orally active inhibitor of JAK2 with excellent selectivity, PK profile, and in vivo efficacy in animal models.
